Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | Future perspectives on CAR-T therapy for multiple myeloma

Nikhil Munshi • 10 Jun 2022
EHA 2022
Multiple Myeloma CAR-T

Nikhil Munshi, MD, Dana-Farber Cancer Institute, Boston, MA, highlights some of the ongoing research in CAR-T therapy for multiple myeloma including increasing capacity and speed of production, as well as increasing expression of BCMA, and a new target being currently evaluated – GPRC5D. Prof. Munshi also notes that some patients treated with CAR-T are benefiting from longer-term maintenance, potentially paving the way for a cure in multiple myeloma. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Disclosures

Advisory Board/Consultant: Adaptive, Abbvie, Amgen, BMS, Janssen, Karyopharm, Legend, Oncopep, Millennium, Novartis, Pfizer DCT

Scientific Founder: Oncopep, DCT

More from Nikhil Munshi

1:56
Long noncoding RNAs represent potential therapeutic targets in multiple myeloma
Nikhil Munshi • 11 Dec 2023
1:05
Alterations to the bone marrow microenvironment in patients with AL amyloidosis
Nikhil Munshi • 11 Dec 2023
2:42
Immunotherapeutic approaches to overcoming drug resistance in venetoclax-exposed patients with MM
Nikhil Munshi • 11 Dec 2023
2:02
Updated Phase I study results of PHE885 in patients with R/R multiple myeloma
Nikhil Munshi • 9 Jun 2023

Related Videos

3:54
Cilta-cel as a potential new SoC for R/R multiple myeloma: insights from the CARTITUDE-4 trial
Roberto Mina • 23 Apr 2024
1:41
CRS and neurotoxicity in bispecific antibody and CAR-T therapy for multiple myeloma
Eden Biltibo • 15 Apr 2024
0:36
The recent expanded FDA approval of cilta-cel and ide-cel into earlier lines of myeloma treatment
Sergio Giralt • 16 Apr 2024
1:48
Tackling underrepresentation of minorities in CAR-T clinical trials
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals